Dr Luis Raez gives his thoughts on key studies in lung cancer from ASCO 2024.
He covers the following studies:
CROWN: 5 year progression-free survival and safety from study into lorlatinib versus crizotinib in treatment-naïve patients with advanced ALK positive non-small cell lung cancer. | |
ADRIATIC: Durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer. | |
LAURA: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated non-small cell lung cancer. |